M05.229 Medicare coverage policies

27 active Medicare policies list M05.229. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.

Get free alerts for M05.229

Free account. Policy pages stay open to everyone.

Medicare policies listing M05.229

LCD · NORIDIAN-JE-L39116

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

JE · Effective Nov 12, 2023

LCD · NORIDIAN-JF-L39116

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

JF · Effective Nov 12, 2023

LCD · PALMETTO-JJ-L39128

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

JJ · Effective Apr 30, 2023

LCD · PALMETTO-JM-L39128

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

JM · Effective Apr 30, 2023

LCD · NOVITAS-JH-L35062

Biomarkers Overview

JH · Effective Oct 1, 2015

LCD · NOVITAS-JL-L35062

Biomarkers Overview

JL · Effective Oct 1, 2015

LCD · NGS-J6-L33394

Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

J6 · Effective Oct 1, 2015

LCD · NGS-JK-L33394

Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

JK · Effective Oct 1, 2015

LCD · PALMETTO-JJ-L35677

M05.229 Medicare coverage policies

Medicare policies listing M05.229

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Biomarkers Overview

Biomarkers Overview

Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

Infliximab

M05.229 Medicare coverage policies

Medicare policies listing M05.229

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Biomarkers Overview

Biomarkers Overview

Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

Infliximab

Infliximab

Off-label Use of Rituximab and Rituximab Biosimilars

Off-label Use of Rituximab and Rituximab Biosimilars

Pharmacogenomics Testing

Pharmacogenomics Testing

Sedimentation Rate, Erythrocyte

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Biomarkers Overview

Billing and Coding: Infliximab

Billing and Coding: Infliximab and biosimilars

Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars

Billing and Coding: Sedimentation Rate, Erythrocyte